In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease.

Figure 2c shows that, with respect to untreated mice or those treated with Sc.Aβ, the Aβ 25-35 treatment induced highly significant deficits in mice performance both as step-through latency and as escape latency during the retention session ( Fig. 2c,d , respectively).

also in 132,142 other papers

infusion of ARN14140 for 7 days tended to prevent the increase in TNFα levels, although the ANOVA failed to reach significance, a similar attenuation was noted with both regimens, 2.5 and 7.5 μg/day.

also in 4,113 other papers

Nonetheless a clear trend of increased density of cholinergic terminals was observed in those mice receiving ARN14140 .

also in 19,460 other papers